== Information about Olaratumab ==Olaratumab is a human monoclonal antibody to the platelet-derived growth factor (PDGF) receptor alpha and an antineoplastic agent used in the therapy of advanced soft tissue sarcoma.
Liver safety of Olaratumab
Olaratumab has not been linked to serum enzyme elevations during therapy or to idiosyncratic acute liver injury.
Mechanism of action of Olaratumab
Olaratumab (oh" lar at' ue mab) is a recombinant human monoclonal IgG1 antibody to the platelet-derived growth factor receptor alpha. Signaling through PDGF receptors promotes cell proliferation and angiogenesis. Inhibition of the PDGF signaling decreases formation of new blood vessels, which plays an important role in growth and spread of cancer cells. When used in combination with other antineoplastic agents, olaratumab has been shown to extend recurrence-free survival in several forms of advanced cancer.
FDA approval information for Olaratumab
Olaratumab was approved in the United States in 2016 for use in combination with doxorubicin for refractory, advanced soft tissue sarcoma.
Dosage and administration for Olaratumab
Olaratumab is available in solution in single use vials of 500 mg in 50 mL or 190 mg in 19 mL (10 mg/mL) under the brand name Lartruvo. The typical dose is 15 mg/kg intravenously over 60 minutes on days 1 and 8 of each 21-day cycle. Premedication with diphenhydramine and dexamethasone is recommended with the initial dose.
Side effects of Olaratumab
Olaratumab is administered with doxorubicin and this combination has significant adverse side effects, including nausea and vomiting, diarrhea, fatigue, anorexia, abdominal pain, alopecia, peripheral neuropathy, neutropenia, and stomatitis. Uncommon, but potentially severe adverse events include severe infusion reactions, hypersensitivity reactions, and embryofetal toxicity.